Amplification, overexpression, or mutations of epidermal growth factor receptor (EGFR) leading to the activations of both Ras-ERK and Ras-PI3K-Akt signaling pathways are detected in various human cancers [32–34]. This evidence concerns the gene EGFR and cancer.